Lipocalin-2-mediated astrocyte pyroptosis promotes neuroinflammatory injury via NLRP3 inflammasome activation in cerebral ischemia/reperfusion injury

被引:37
|
作者
Li, Juanji [1 ]
Xu, Pengfei [2 ]
Hong, Ye [3 ]
Xie, Yi [1 ]
Peng, Mengna [1 ]
Sun, Rui [4 ]
Guo, Hongquan [1 ]
Zhang, Xiaohao [3 ]
Zhu, Wusheng [1 ]
Wang, Junjun [5 ]
Liu, Xinfeng [1 ,2 ]
机构
[1] Nanjing Univ, Nanjing Jinling Hosp, Affiliated Hosp, Dept Neurol,Med Sch, Nanjing 210002, Jiangsu, Peoples R China
[2] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Neurol, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China
[3] Nanjing Med Univ, Nanjing Hosp 1, Dept Neurol, Nanjing 210002, Jiangsu, Peoples R China
[4] Second Mil Med Univ, Naval Med Univ, Shanghai Changhai Hosp, Dept Neurol, Shanghai 200433, Peoples R China
[5] Nanjing Univ, Affiliated Jinling Hosp, Dept Clin Lab, Med Sch, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China
关键词
Cerebral ischemia; reperfusion injury; Astrocyte; Pyroptosis; LCN2; NLRP3; inflammasome; REACTIVE ASTROCYTES; BRAIN-INJURY; CELL-DEATH; SUBARACHNOID HEMORRHAGE; PROTEIN FAMILY; PORE FORMATION; APOPTOSIS; POLARIZATION; MECHANISM; ISCHEMIA;
D O I
10.1186/s12974-023-02819-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundNeuroinflammation is a vital pathophysiological process during ischemic stroke. Activated astrocytes play a major role in inflammation. Lipocalin-2 (LCN2), secreted by activated astrocytes, promotes neuroinflammation. Pyroptosis is a pro-inflammatory form of programmed cell death that has emerged as a new area of research in stroke. Nevertheless, the potential role of LCN2 in astrocyte pyroptosis remains unclear.MethodsAn ischemic stroke model was established by middle cerebral artery occlusion (MCAO) in vivo. In this study, in vitro, oxygen-glucose deprivation and reoxygenation (O/R) were applied to cultured astrocytes. 24p3R (the LCN2 receptor) was inhibited by astrocyte-specific adeno-associated virus (AAV-GFAP-24p3Ri). MCC950 and Nigericin sodium salt (Nig) were used to inhibit or promote the activation of NLRP3 inflammasome pharmacologically, respectively. Histological and biochemical analyses were performed to assess astrocyte and neuron death. Additionally, the neurological deficits of mice were evaluated.ResultsLCN2 expression was significantly induced in astrocytes 24 h after stroke onset in the mouse MCAO model. Lcn2 knockout (Lcn2(-/-)) mice exhibited reduced infarct volume and improved neurological and cognitive functions after MCAO. LCN2 and its receptor 24p3R were colocalized in astrocytes. Mechanistically, suppression of 24p3R by AAV-GFAP-24p3Ri alleviated pyroptosis-related pore formation and the secretion of pro-inflammatory cytokines via LCN2, which was then reversed by Nig-induced NLRP3 inflammasome activation. Astrocyte pyroptosis was exacerbated in Lcn2(-/-) mice by intracerebroventricular administration of recombinant LCN2 (rLCN2), while this aggravation was restricted by blocking 24p3R or inhibiting NLRP3 inflammasome activation with MCC950.ConclusionLCN2/24p3R mediates astrocyte pyroptosis via NLRP3 inflammasome activation following cerebral ischemia/reperfusion injury.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Lipocalin-2-mediated astrocyte pyroptosis promotes neuroinflammatory injury via NLRP3 inflammasome activation in cerebral ischemia/reperfusion injury
    Juanji Li
    Pengfei Xu
    Ye Hong
    Yi Xie
    Mengna Peng
    Rui Sun
    Hongquan Guo
    Xiaohao Zhang
    Wusheng Zhu
    Junjun Wang
    Xinfeng Liu
    Journal of Neuroinflammation, 20
  • [2] NLRP3 Inflammasome Activation-Mediated Pyroptosis Aggravates Myocardial Ischemia/Reperfusion Injury in Diabetic Rats
    Qiu, Zhen
    Lei, Shaoqing
    Zhao, Bo
    Wu, Yang
    Su, Wating
    Liu, Min
    Meng, Qingtao
    Zhou, Bin
    Leng, Yan
    Xia, Zhong-yuan
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2017, 2017
  • [3] Protective Effects of Remimazolam on Cerebral Ischemia/Reperfusion Injury in Rats by Inhibiting of NLRP3 Inflammasome-Dependent Pyroptosis
    Shi, Min
    Chen, Jing
    Liu, Tianxiao
    Dai, Weixin
    Zhou, Zhan
    Chen, Lifei
    Xie, Yubo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 413 - 423
  • [4] NLRP3 Inflammasome Activation: A Therapeutic Target for Cerebral Ischemia-Reperfusion Injury
    Wang, Lixia
    Ren, Wei
    Wu, Qingjuan
    Liu, Tianzhu
    Wei, Ying
    Ding, Jiru
    Zhou, Chen
    Xu, Houping
    Yang, Sijin
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2022, 15
  • [5] The Interplay between Autophagy and NLRP3 Inflammasome in Ischemia/Reperfusion Injury
    Lv, Shuangyu
    Liu, Huiyang
    Wang, Honggang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [6] Sodium Danshensu ameliorates cerebral ischemia/reperfusion injury by inhibiting CLIC4/NLRP3 inflammasome-mediated endothelial cell pyroptosis
    Zhang, Xiaolu
    Yang, Qiuyue
    Zhang, Ruifeng
    Zhang, Yilin
    Zeng, Wenyun
    Yu, Qun
    Zeng, Miao
    Gan, Jiali
    Li, Huhu
    Yang, Lin
    Gao, Qing
    Jiang, Xijuan
    BIOFACTORS, 2024, 50 (01) : 74 - 88
  • [7] Mitochondrial dysfunction induces NLRP3 inflammasome activation during cerebral ischemia/reperfusion injury
    Gong, Zhe
    Pan, Jingrui
    Shen, Qingyu
    Li, Mei
    Peng, Ying
    JOURNAL OF NEUROINFLAMMATION, 2018, 15
  • [8] Tetrandrine alleviates cerebral ischemia/reperfusion injury by suppressing NLRP3 inflammasome activation via Sirt-1
    Wang, Jun
    Guo, Ming
    Ma, Ruojia
    Wu, Maolin
    Zhang, Yamei
    PEERJ, 2020, 8
  • [9] Daucosterol pretreatment ameliorates myocardial ischemia reperfusion injury via ROS-mediated NLRP3 inflammasome activation
    Zhao, Guixiang
    Ma, Xiaoyun
    Juledezi-Hailati
    Bao, Zhen
    Maerjiaen-Bakeyi
    Liu, Zhiqiang
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (05) : 1031 - 1036
  • [10] Inhibition of perilipin 2 attenuates cerebral ischemia/reperfusion injury by blocking NLRP3 inflammasome activation both in vivo and in vitro
    Liu, Xu-Ying
    Li, Qiu-Shi
    Yang, Wen-Hai
    Qiu, Yue
    Zhang, Fei-Fei
    Mei, Xiu-Hui
    Yuan, Qi-Wen
    Sui, Ru-Bo
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2023, 59 (03) : 204 - 213